Glax­o­SmithK­line of­floads roy­al­ty rights for 2 can­cer drugs in $342M wind­fall it will use to fi­nance con­sumer spin­off

As Glax­o­SmithK­line con­tin­ues plans to spin off its Pfiz­er-part­nered con­sumer health di­vi­sion, the British phar­ma pulled in a new heap­ing of cash to ac­com­plish that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER